Pharmaceuticals UAE

UAE Gene Therapy for Hemophilia Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

UAE Gene Therapy for Hemophilia Market Industry Trends and Forecast to 2034: Segmented by (Type, Vector, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UAE · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.8 Mn Placeholder estimate
Estimate 2025 $2.4 Mn 0.5% of the global market
Projected 2034 $27.8 Mn 1,051.9% Adds $25.3 Mn over 9 forecast years
CAGR 2025–2034 31.2% Faster than 97% of 180 Pharmaceuticals markets here
Key players 5
  • UAE is 0.48% of the global market.
  • In Middle East, the largest is Saudi Arabia at $8.7 Mn.
  • Fastest growing: Saudi Arabia at 31.8% a year.
  • UAE ranks 2nd of 2 by size in Middle East.

Market size projection

UAE

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$25.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Gene Therapy for Hemophilia Market market size by year, UAE
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.8 Mn — —
2025 (base) $2.4 Mn +$0.6 Mn —
2026 (forecast) $3.2 Mn +$0.8 Mn +31.2%
2027 (forecast) $4.1 Mn +$1.0 Mn +72.1%
2028 (forecast) $5.4 Mn +$1.3 Mn +125.8%
2029 (forecast) $7.1 Mn +$1.7 Mn +196.3%
2030 (forecast) $9.4 Mn +$2.2 Mn +288.7%
2031 (forecast) $12.3 Mn +$2.9 Mn +410%
2032 (forecast) $16.1 Mn +$3.8 Mn +569.2%
2033 (forecast) $21.2 Mn +$5.0 Mn +778%
2034 (forecast) $27.8 Mn +$6.6 Mn +1,051.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

UAE Gene Therapy for Hemophilia Market Analysis at a glance
Market size, 2025$2.4 Mn placeholder estimate
Forecast, 2034$27.8 Mn placeholder estimate
Growth (CAGR), 2025–203431.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, vector and end user (see all)
Key playersBioMarin, CSL Behring, Pfizer Inc., Roche, Sangamo Therapeutics (see all)
Regulator in the UAEEDESource: Emirates Drug Establishment. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The UAE Gene Therapy for Hemophilia Market Analysis Executive Summary

Gene therapies for hemophilia give patients a working copy of the clotting factor gene, so they may need fewer or no regular infusions.

Key segments of the gene Therapy for Hemophilia market include type (Hemophilia A and Hemophilia B) and vector (AAV5 and AAV Other Serotypes).

Bar chart: UAE Gene Therapy for Hemophilia market size, 2024–2034, placeholder estimates. $1.8 Mn in 2024, $2.4 Mn in 2025 and $27.8 Mn in 2034, 31.2% CAGR.
UAE Gene Therapy for Hemophilia market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

UAE Gene Therapy for Hemophilia Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Therapy for Hemophilia market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Therapy for Hemophilia market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Gene Therapy for Hemophilia Market in UAE

The gene Therapy for Hemophilia market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Gene Therapy for Hemophilia Market in UAE

Gene Therapy for Hemophilia in the UAE: rules and payment

The Emirates Drug Establishment (EDE), set up in 2023, is taking over the regulation of medicines from the Ministry of Health and Prevention.⁠[1] Since January 2025, basic health insurance has been mandatory for all private-sector employees and domestic workers in every emirate.⁠[2]

[1] Emirates Drug Establishment. Checked 14 Nov 2026.

[2] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Therapy for Hemophilia. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UAE.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Gene Therapy for Hemophilia right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Gene Therapy for Hemophilia in context

The UAE compared

  • Health spending per person: 2,402 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 9 countries we cover in Middle East.[1]
  • Doctors: 2.99 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 3rd highest of the 9 countries we cover in Middle East.[2]
  • People aged 65 and over: 1.8% of people (2025). World: 10.4% of people (2025). 8th highest of the 9 countries we cover in Middle East.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Gene Therapy for Hemophilia market in the UAE?
Placeholder estimate: about $2.4 Mn in 2025, rising to about $27.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Gene Therapy for Hemophilia market in the UAE growing?
Placeholder estimate: about 31.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Gene Therapy for Hemophilia market report cover?
The report splits the market by type (Hemophilia A, Hemophilia B), vector (AAV5, AAV Other Serotypes) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Gene Therapy for Hemophilia market?
Key players include BioMarin, CSL Behring, Pfizer Inc., Roche and Sangamo Therapeutics.
What is driving the Gene Therapy for Hemophilia market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
Who regulates Gene Therapy for Hemophilia in the UAE?
The Emirates Drug Establishment (EDE), set up in 2023, is taking over the regulation of medicines from the Ministry of Health and Prevention. Source: Emirates Drug Establishment. Checked 14 Nov 2026.
How is healthcare paid for in the UAE?
Since January 2025, basic health insurance has been mandatory for all private-sector employees and domestic workers in every emirate. Source: Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
How much research is published on Gene Therapy for Hemophilia?
PubMed lists 291 papers on Gene Therapy for Hemophilia added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in UAE

See all

Related on cell and gene therapy and rare diseases

See the topic